Oncology Pharmacists Connect Meeting Promises Clinical Updates, Opportunities to Advance Patient Care

Pharmacy Times will be covering the 2023 Oncology Pharmacists Connect meeting June 15 to 17 in Austin, Texas. The conference will bring together key opinion leaders, oncology experts, and pharmacists from across the country to discuss the latest research and updates on a variety of clinical topics.

The 2023 Oncology Pharmacists Connect meeting will be held June 15 to 17 in Austin, Texas.

The increasingly complex landscape of clinical oncology is advancing the role of pharmacists. The meeting aims to bring together key opinion leaders to discuss solutions for responding to the rapidly evolving evidence announced at the American Society of Clinical Oncology (ASCO) Annual Meeting. The agenda includes multiple practice settings, recently presented data, and resources to implement new therapies and solutions.

“We’re going to really focus in on a lot of the post-ASCO data that I think is going to be so timely and relevant to the treatment of our patients, and also upcoming new medication approvals,” said program chair Ryan Haumschild, PharmD, MS, MBA, in an interview with Pharmacy Times. “We’re also going to be focused on unique disease states; I’m thinking of solid tumors and hematologic malignancies, like multiple myeloma, [which is] the one that I’m actually getting to lead personally.”

Pharmacy Times will be covering the meeting live, with session coverage as well as interviews with experts. Stay tuned on PharmacyTimes.com for exclusive coverage, including:

• An interview with Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at the Mayo Clinic, about the future of patient care in melanoma, particularly with immunotherapy and targeted therapies. Finnes will discuss which patients are most likely to see success with immunotherapies, the most commonly targeted genes for targeted therapies, and unique challenges associated with some melanomas, such as mucosal and ocular melanoma.
• A session titled “Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non–Small Cell Lung Cancer” will explore new therapies and approaches for treating this challenging disease. Presenters Stefanie L. Houseknecht, PharmD, BCOP, and Chelsey Lindner, PharmD, BCOP, CSP, will lead the session and provide their insights.
• An interview with Danielle Roman, PharmD, BCOP, manager of Oncology Clinical Pharmacy Services at Allegheny Health Network, to discuss her presentation titled “New Evidence in Breast Cancer and the Impact to Care.” Roman will review updates in HER2–low breast cancer, the use of targeted therapies in HR–positive breast cancer, the unique challenges with triple-negative breast cancers, and more.
• A session reviewing new advancements transforming treatment paradigms for prostate cancer. With new therapies ranging from hormone therapy to PARP inhibitors and immunotherapies, presenters will review key information for pharmacists and how they can best implement these approaches in clinical practice.
• An interview with program chair Ryan Haumschild, PharmD, MS, MBA, discussing his own presentation titled “A Look at Multiple Myeloma and the Latest Advancements in BCMA–Targeted Approaches.” Haumschild will review key updates on CAR T-cell therapies, bispecific antibodies, and antibody drug conjugates for patients with multiple myeloma, as well as evidence for optimal treatment approaches and the role of pharmacists.

Following Pharmacy Times’ coverage of the conference on our website and social media channels for all of the latest updates. Click here for more information on registering for Oncology Pharmacists Connect.